Every 10-Q that Unicycive Therapeutics, Inc. (UNCY) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow UNCY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full UNCY filings page.
Unicycive Therapeutics, Inc. reported a larger net loss while significantly strengthening its cash position for the six months ended June 30, 2026. Net loss was $14.5 million compared with $5.9 million a year earlier, driven by higher research and development and general and administrative expenses totaling $18.6 million.
Other income included a $3.2 million gain from changes in the fair value of warrant liabilities and $0.8 million of interest income, which partially offset operating losses. Operating cash outflows were $13.8 million, while financing activities provided $34.0 million of net proceeds from sales of 5,278,767 shares under an at-the-market program.
Cash, cash equivalents and marketable securities increased to $61.4 million as of June 30, 2026, from $41.3 million at December 31, 2025, and total assets were $72.0 million. Management states it believes available resources are sufficient to fund operations for at least one year. The company also discloses ongoing shareholder litigation relating to disclosures about oxylanthanum carbonate.
Unicycive Therapeutics filed its Q3 2025 10-Q, showing larger resources and continued R&D investment. Cash and cash equivalents were $42.7 million as of September 30, 2025, up from $26.1 million at year-end 2024, reflecting equity activity. Total assets were $50.6 million and stockholders’ equity was $37.5 million.
The company reported a Q3 2025 net loss of $6.0 million and a nine‑month net loss of $11.9 million. Operating expenses were $7.3 million in Q3 (R&D $3.0 million; G&A $4.4 million). Other income benefited from a $1.1 million non‑cash gain from the change in fair value of warrant liabilities in Q3, and $9.8 million for the nine months.
Operating cash outflows were $23.3 million for the nine months. To fund operations, Unicycive sold 8,046,736 shares via its sales agreement with Guggenheim at an average price of $4.94, paying $1.2 million in commissions and receiving approximately $38.6 million in net proceeds. A 1‑for‑10 reverse stock split became effective in June 2025. 20,850,363 shares were outstanding as of September 30, 2025, and 21,491,396 as of November 12, 2025.
Unicycive Therapeutics (UNCY) reported interim financial results for the quarter ended June 30, 2025 showing $22.3 million in cash and total assets of $30.0 million, down slightly from $31.7 million at year-end. Total liabilities fell materially to $13.6 million from $24.2 million, driven largely by a decline in the warrant liability from $18.9 million to $10.2 million, which reduced reported expense volatility.
The company recorded a six-month net loss of $5.9 million, an improvement from a $11.1 million loss in the prior-year period, as operating expenses decreased to $15.0 million from $16.6 million. Cash used in operating activities was $17.3 million for the six months, and net cash provided by financing activities was $13.5 million, including $12.6 million from a secondary offering. Management states it believes it has sufficient resources for at least one year under current plans. The filing also discloses a 1-for-10 reverse stock split effective June 20, 2025 and ongoing reliance on future financing to complete development and commercial efforts.